Puma Biotechnology, Inc. Approves Promotion of Richard P. Bryce from Senior Vice President, Clinical Research and Development to Chief Medical and Scientific Officer
August 02, 2017 at 09:28 pm
Share
On July 31, 2017, the Board of Directors of Puma Biotechnology, Inc. approved the promotion of Richard P. Bryce, MBChB, MRCGP and MFPM, from Senior Vice President, Clinical Research and Development to Chief Medical and Scientific Officer of the company, effective August 1, 2017.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
Puma Biotechnology, Inc. Approves Promotion of Richard P. Bryce from Senior Vice President, Clinical Research and Development to Chief Medical and Scientific Officer
PUMA BIOTECHNOLOGY, INC. 
